Real-world survival and prognostic factors in WHO 2021 classified gliomas treated with chemo-radiotherapy.

ABSTRACT: The 2021 WHO glioma classification integrates molecular profiling, but outcome data for these patients are limited. We retrospectively analyzed 179 patients (median age 53) with WHO 2021-classified gliomas (grade 2: n = 45, grade 3: n = 51, grade 4: n = 83) treated with surgery and radio(chemo)therapy across four centers in Poland and France. Chemotherapy was administered to 74.9% of patients, with a median radiotherapy dose of 60 Gy (range 32.5-80 Gy). IDH1/2 mutations were identified in 55.3% and 1p/19q codeletion in 22.4%. Patients with IDH1/2 mutations had significantly longer progression-free survival (PFS, 7.7 vs. 1.0 years) and overall survival (OS, 8.2 vs. 2.5 years), both p < 0.01. 1p/19q codeletion was associated with prolonged PFS (7.7 vs. 1.6 years, p < 0.01). In grade 3 glioma

SUBMITTER: Bilski M 

PROVIDER: S-EPMC12575803 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature